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ABSTRACT
Mesoporous silicon has become amaterial of high interest for drug delivery due to its
outstanding internal surface area and inherent biodegradability. We have previously
reported the preparation of mesoporous silicon microparticles (MS-MPs) synthe-
sized by an advantageous electrochemical method, and showed that due to their inner
structure they can adsorb proteins in amounts exceeding themass of the carrier itself.
Protein release from these MS-MPs showed low burst eVect and fast delivery kinetics
with complete release in a few hours. In this work, we explored if tailoring the size of
the inner pores of the particles would retard the protein release process. To address
this hypothesis, three new MS-MPs prototypes were prepared by electrochemical
synthesis, and the resulting carriers were characterized for morphology, particle
size, and pore structure. All MS-MP prototypes had 90 mmean particle size, but
depending on the current density applied for synthesis, pore size changed between
5 and 13 nm. The model protein -chymotrypsinogen was loaded into MS-MPs
by adsorption and solvent evaporation. In the subsequent release experiments, no
burst release of the protein was detected for any prototype. However, prototypes with
larger pores (>10 nm) reached 100% release in 24–48 h, whereas prototypes with
small mesopores (<6 nm) still retained most of their cargo after 96 h. MS-MPs with
6 nm pores were loaded with the osteogenic factor BMP7, and sustained release
of this protein for up to two weeks was achieved. In conclusion, our results confirm
that tailoring pore size canmodify protein release fromMS-MPs, and that prototypes
with potential therapeutic utility for regional delivery of osteogenic factors can be
prepared by convenient techniques.
Subjects Bioengineering, Drugs and Devices
Keywords Mesoporous silicon, Pore size, Controlled release, Microparticles, Protein delivery,
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INTRODUCTION
Mesoporous silicon (MS)-based materials are currently investigated in a variety of
systems for drug delivery and tissue engineering applications (Anglin et al., 2008; Santos,
2014). Their main advantage lies on their outstanding surface area arising from the fine
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mesoporous structure that allows remarkable drug loadings to be achieved just by plain
adsorption (Prestidge et al., 2008). MS is also biocompatible (Canham, 1995; Godin et
al., 2008; Salonen et al., 2008), and degrades in the body to silicates (SiO2) (Canham,
1995; Salonen et al., 2008; Pastor et al., 2009) that are eliminated by renal excretion
(Popplewell et al., 1998). Silicates have FDAGRAS status, and even safety margins for silica
nanoparticles administered intravenously start to be established (Yu et al., 2013). Inspired
by these properties, researchers have investigated silicon-based carriers in a variety of
formats (i.e., scaVolds, microparticles, nanoparticles, etc.) for delivering hydrophobic and
hydrophilic drugs (Anglin et al., 2008; Prestidge et al., 2008; Salonen et al., 2008). MS-based
materials have also been proposed for delivering drug-loaded nanoparticles within the
concept of multistage delivery vehicles (Tasciotti et al., 2008).
Devices composed of a crystalline mesoporous silicon matrix are alternatives to
silica mesoporous structures (Kresge et al., 1992), but unlike those, they do not require
mesophase template removal for their preparation. Mesoporous silicon can be prepared
by stain-etching or electrochemical anodizing of silicon. Both methods result in suitable
mesoporous (nanostructured) materials, but the stain-etching method is less controlled
with respect to pore homogeneity, and often leaves an untreated crystalline silicon core in-
side the particles. Medical materials prepared from stain-etchedmesoporous silicon should
be additionally checked for complete removal of toxic nitric oxide residues. The electro-
chemical method for MS production is therefore more medical-friendly, and recently its
scalability has been considerably improved (Makushok,Matveyeva & Pastor, 2012).
The desired nanostructure of MS fabricated by electrochemical methods can be easily
achieved by a simple tuning of the preparation conditions; first of all, the applied current
density. Even though these inner nanostructure parameters (pore size, overall porosity,
particle size, etc.) are important for MS silicon drug carriers, they cannot assure by them-
selves optimal drug payloads. The interaction between the drug and the carrier surface
needs also to be engineered, and thus the surface modification and functionalization of
MS nanostructures has been extensively studied in recent years (Jarvis, Barnes & Prestidge,
2011; Jarvis, Barnes & Prestidge, 2012; Barnes, Jarvis & Prestidge, 2013). Among diVerent
techniques, a simple oxidation is frequently performed that converts the outer surfaces of
crystallinemesoporous silicon to amesoporous silica replica (Kresge et al., 1992).
In a previous publication from our group,MSmicroparticles (MS-MPs) with an average
pore size of 35 nm were prepared by an electrochemical method and stabilized by thermal
oxidation. These MS-MPs were successfully loaded by absorption equilibrium with two
model proteins, insulin and bovine serum albumin BSA (Pastor et al., 2011). Although
these proteins were released from a vehicle in a controlled manner, the process was fast
(80–100% release in less than 2 h), and consequently only suitable for some applications
such asmucosal drug delivery.
Previous studies with hydrogels (Peppas et al., 2000), solid polymers (Sandor et al.,
2001), and other mesoporous materials (Santos, Radin &Ducheyne, 1999) have shown that
modulation of the inner nanostructure of the carrier can change the kinetics of drug
release. We proposed that similar principles should apply for controlling the release
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of proteins from electrochemically synthesized MS-MPs. To address this hypothesis,
we prepared MS-MPs with diVerent pore sizes and explored how changes in inner
nanostructure can influence the release of loaded proteins. This study was performed
initially with the model protein -chymotrypsinogen (aCT); then, considering the
bioactivity of MS materials for orthopedic regeneration (Canham, Reeves & Newey, 1999;
Pastor et al., 2007; Sun et al., 2007), we loaded a protein of therapeutic interest for this
application, bonemorphogenetic protein-7 (BMP7).
MATERIALS AND METHODS
Materials
Boron doped silicon with diVerent resistivity, 0.01–0.02 and 10–20 cm, was purchased
from Si Materials (Germany); wafer diameter was 100.0  0.5 mm and thickness of
525 25 m (pI D 2–3.5). Fluoric acid (HF) (48%) was purchased from Riedel de Hae¨n
(Germany) and ethanol (96%) from Panreac (Barcelona, Spain). Synthetic air (N2 with
21% of O2) was provided from AbelloLinde S.A. (Barcelona, Spain). Avidin-peroxidase
conjugate, -chymotrypsinogen A (aCT) from bovine pancreas (pI D 9:5; Mw D
25:7 kDa), and 2, 20-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) were obtained from
Sigma Aldrich (Madrid, Spain). Recombinant human Bone Morphogenetic Protein-7
(BMP7) (pI D 8:1; Mw D 28:8 kDa), polyclonal antibody rabbit anti-human BMP7,
and biotinylated polyclonal antibody rabbit anti-human BMP7 were purchased from
PeproTech (London, UK). All other solvents and chemicals used were high-grade purity.
Preparation of mesoporous silicon microparticles (MS-MPs)
MS-MPs were obtained by an electrochemical method similar to that previously described
by us (Pastor et al., 2009). The main diVerence was the use of a 1:1 HF:Ethanol electrolyte,
and special cyclic regimes with etch-stops in order to improve the homogeneity of
pore sizes distribution along with the in-depth etching (Bychto et al., 2008). A constant
current step (40 or 60 mA/cm2 for 5–10 s) was followed by an etch-stop step (no current
applied for 2–5 s) in cyclic periods. After obtaining a MS layer of 150 m thickness,
the electrochemical process was stopped, and the Si wafer was washed thoroughly with
distilled water, dried, and the porous material was scratched from the remaining Si
substrate. The obtainedMS was subjected to a thermal oxidation under a flow of synthetic
air for 1 h at 500 or 650 C (Programat P200 equipped with a vacuum pump VP3 and gas
inlet; Ivoclar-Vivadent, Inc., Amherst, New York, US). To reduce the particle size to the
micrometer scale, the MSmaterial was milled and sieved in cascade. The fraction between
75 and 100 mwas selected for further studies. Henceforth, this fraction is referred to as
MS-MPs. The preparation conditions for the three diVerent MS-MP prototypes studied
in this work are summarized in Table 1. For example, prototype B was prepared from Si
wafer of 0.01–0.02 cm resistivity, under a current density of 40mA=cm2 applied for 10 s,
and then interrupted by a 2 s interval of zero current (etch-stop). This regime was cyclically
repeated for a few hours until the 150 m porous layer was grown. After recollecting the
porousmaterial, thematerial was thermally oxidized at 650 for one hour.
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Table 1 Preparation conditions for diVerent mesoporous silicon prototypes synthesized by the elec-
trochemical method under special cyclic regimes with etch-stop (zero current) applied after each
anodizing interval. Three diVerent prototypes (A–C) were prepared and tested in this study, diVering
in silicon waver resistivity, current densities, etch-stop times, and thermal oxidation temperatures.
Prototype Si wafer
resistivity
( cm)
Current density
(mA=cm2//
anodizing
time (s)
Etch stop
time (s)
Oxidation
temperature (C)
A 0.01–0.02 40/5 5 500
B 0.01–0.02 40/10 2 650
C 10–20 60/5 2 550
Characterization of MS-MPs
The porosity of the porous siliconmaterials was determined gravimetrically by comparing
the mass of the silicon wafer before and after anodizing as previously described (Pastor
et al., 2011). Particle sizes were analyzed with a Mastersizer 2000 (Malvern Instruments,
Malvern, Worcestershire, UK). MS-MPs morphology was visualized by high resolution
Scanning ElectronMicroscopy (SEM; Hitachi S4500; Hitachi, Tokyo, Japan). Additionally,
the Brunauer- Emmett-Teller (BET) surface area of the MS-MPs was determined by N2
adsorption–desorption isotherms (Micrometrics ASAP 2020 V3.04H; Micromeritics
France S.A.,Verneuil-en-Halatte, France). Pore size was calculated from the same N2
adsorption data, by the Barroett-Joyner-Halenda (BJH)method.
Protein loading
Protein loading was carried out by solvent evaporation (Prestidge et al., 2008). Briefly, 20 L
of the model protein aCT (3mg/mL) or BMP7 (5 g/mL) in aqueous solutions were added
to a fixed amount of MS-MPs (1 mg). The samples were gently vortexed for 10 s, and then
incubated under mild agitation at 37 C until total evaporation of solvent was reached and
all amounts of proteins incorporated into theMS-MPs (about 7 h). The theoretical protein
loadings were: 60 g/mg ofMS-MPs for aCT, and 0.1 g/mg ofMS-MPs for BMP7. Loaded
MS-MPs were freeze-dried and stored at 20 C until use.
In vitro release studies
Samples comprising 1 mg of MS-MPs loaded with aCT or BMP7 were incubated with
500 L of PBS (USP 38-NF 33, pH 7.4) under agitation (100 rpm, Titramax 1000; Hein-
dolf, Schwabach, Germany) at 37 C (Inkubator 1000, Heindolf, Schwabach, Germany).
At scheduled time points, release samples were collected, and centrifuged at 7000 RCF for
10 min at 4 C (Microfuge 22R; Beckman Coulter, Brea, California, USA). The amounts
of aCT in supernatants were determined by the bicinchoninic acid method (Micro BCA
protein Assay Kit; Pierce Biotechnology Inc., Rockford, Illinois, USA), and those of BMP7
by ELISA, as previously reported by us (Reguera-Nun˜ez et al., 2014). Amounts of released
protein are expressed as percentage of a total protein mass added at the loading stage since
the wholemass was considered as absorbed upon solvent evaporation.
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Figure 1 Morphological and physicochemical properties of mesoporous silicon microparticles (MS-
MPs). (A) SEM image of MS-MPs (bar is 200 m); (B) particle size distribution of the diVerent MS-MP
prototypes measured with a particle size analyzer; (C) example of a SEM image of the surface of MS-MPs
(corresponding to prototype A, bar is 800 nm); (D) N2 adsorption isotherms, volume adsorbed vs.
relative pressure (P=P0), for the diVerent MS-MP prototypes.
RESULTS AND DISCUSSION
Characterization of different MS-MPs carriers
Mesoporous silicon microparticles (MS-MPs) were prepared by electrochemical etching,
thermal stabilization, and milling to reduce the particle sizes. The resulting powder was
sorted by sieving. The particles of the selected fraction (i.e., the MS-MPs) were irregular
in shape, but homogeneous in size (Fig. 1A). All the MS-MPs prototypes generated
showed a normal distribution of sizes with a mean value around 90 m (Fig. 1B).
This normal particle distribution contrasted with our previous data where the particle
distribution was log-normal (Pastor et al., 2011); this might be related to the diVerent
particle fractions selected on each work (90 m vs. 33 mmean size, respectively). The
mesoporous structure of MS-MPs observed by high resolution SEM (Fig. 1C) revealed the
regular and homogeneous pores propagated along a single direction, as it is common for
electrochemically prepared MS. The SEM analysis, however, might not reveal the smallest
pores of thematerials due their well-known resolution limits.
The inner structure for three diVerent MS-MP prototypes (A–C) prepared under
the conditions summarized in Table 1 was characterized by N2 adsorption–desorption
experiments (Fig. 1D). The data revealed very high specific surface areas for prototypes A
and B (>200 m2=g), but even more for prototype C (350 m2=g) (Table 2). The porosity
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Table 2 Characteristics of the diVerent mesoporous silicon microparticle prototypes. Data represent
means S.D., nD 3.
Prototype Specific surface
(m2=g)
Porosity (%) Pore diameter
(nm)
A 210.2 13 72 6 11.4 0.7
B 224.9 16 53 8 12.4 3
C 350.8 21 60 5 5.8 0.4
of all samples was high (>50%), and the mean pore diameter was12 nm for prototypes
A and B, and 6 nm for prototype C. These pore sizes were significantly smaller than
MS-MPs prepared in our previous work (Pastor et al., 2011), a result of the diVerent
preparation conditions. Due to their tighter internal structure, we expected that the
MS-MPs obtained in this work would bemore suitable for the sustained release of proteins.
Due to the limited number of prototypes studied and the important diVerence in
parameters observed, it is diYcult to draw unequivocal conclusions on the relationships
between theMS-MPs preparation parameters (Table 1) and the resulting carrier properties
(Table 2). Still, under the tested preparation conditions, there is a positive correlation
between the current density and the specific surface area. Also, an inverse correlation
between the applied current density and the mean pore diameter can be noted, although
the doping level of Si wafer might play a dominant role in this correlation. Globally, the
study confirms the possibility to prepare MS-MPs with controllable mesoporous inner
structures by the electrochemical method.
Protein loading in MS-MPs
After characterization of the diVerent MS-MP prototypes, we studied how these systems
are capable of loading and releasing two proteins, aCT and BMP7. The zymogen aCT was
selected as a model protein for screening studies since it has very similar physicochemical
properties (pI and Mw) to BMP7 (see data on ‘Materials’), and we have previously
observed good correlation between encapsulation of both proteins (Reguera-Nun˜ez et al.,
2014). ACT is a zymogen physiologically activated by the gut’s endopeptidases, and does
not activate under the conditions of the loading procedures and release tests applied in this
work. For protein loading in this work we decided to work under forcing conditions, and
we evaporated a protein solution in the presence of theMS-MPs at 37 C. This method has
the main advantage of forcing protein encapsulation, which can be assumed to be close to
100%. BecauseMS-MPs cannot be degraded without harming the loaded protein, we were
unable to quantify the loaded proteins. However, from the final release point of our release
studies (see ‘Pore size can control the release of a model protein (aCT) fromMS-MPs’ and
‘MS-MPs can achieve a 2-week sustained release of antigenically active BMP7’), we can
conclude that>75% of aCTwas loaded in all preparations, and>60% of BMP7.
When using this loading method, the mechanisms that drive protein loading
would be capillary forces and adsorption from a continually concentrating solution
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Figure 2 In vitro release profile of (A) -chymotrypsinogen and (B) BMP7 fromMS-MPs prepared by
the electrochemical method. Data represent means S.D., nD 3.
(Karlsson et al., 2003). Other possible mechanisms would be electrostatic interactions; after
thermal oxidation the MS-MPs surface bears a negative charge as the silicon oxides cover
the entire porous network (Zangooie, Bjorklund&Arwin, 1998). This might aVect the load-
ing and release of cationic proteins such as aCT and BMP7. Under the tested conditions,
the final protein payloads permg of the carrier were 60 g for aCT and 0.1 g for BMP7.
Pore size can control the release of a model protein (aCT) from
MS-MPs
The release of loaded aCT from the three MS-MPs prototypes was analyzed in vitro (PBS,
37 C). No burst release was observed for any of the tested prototypes, suggesting that most
protein is inside the pores and not adsorbed on the outer MS-MP surface (Fig. 2A). This
behavior is in agreement with our previous study on insulin and BSA, where despite of
a faster release (<2 h), only a moderate burst eVect was observed (30%) (Pastor et al.,
2011). In the present work, the burst eVect was drastically reduced, presumably because
of the lower pore size of the carriers, and because of the diVerent procedures for protein
loading (solvent evaporation vs. adsorption equilibrium).
The MS-MPs investigated in this work were able to control protein release for longer
periods of time than the carriers previously reported by us (Pastor et al., 2011): for
prototypes A and B a 100% release was achieved in 30–40 h after incubation at 37 C
in PBS. Prototype C showed even more sustained kinetics, with high retention of aCT
after 96 h (Fig. 2A). However, after 2-weeks, sample C had released 77.2% 4.2 (n D 3)
of the loaded aCT. The slower release should be associated with the nanostructure of the
carriers, mainly to their pore size. Mean pore size was<15 nm for all prototypes studied
here, and 33 nm in our previous work. Prototype C possesses pores with a mean size of
6 nm, half of those of prototypes A and B, and similar to the radius of gyration of aCT,
1.76 nm (Perkins et al., 1993). As observed in other systems (Santos, Radin & Ducheyne,
1999; Peppas et al., 2000; Sandor et al., 2001), when the drug’s radius of gyration is about
the size of pores in the matrix, diVusion might be hindered, and more sustained release
kinetics achieved. When comparing the diVerent prototypes studied in this work, particle
inner structure seems to be the critical factormodulating diVerent release kinetics.
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When comparing the performance of theMS-MP prototypes from this work with those
of our previous work (Pastor et al., 2011), two additional factors need to be considered.
First, the eVect of the chemical diVerences of the proteins tested. Insulin and BSA, used
before, both bear negative charges in PBS, and therefore, their attachment to MS-MPs
surfaced by adsoption shoud be driven mostly by hydrophobic interactions. On the other
hand, aCT is positive in PBS, and therefore, ionic interactions with the silicon oxide on the
surface of MS-MPs can be important to explain protein adsorption/desorption. Another
parameter that could have some limited influence on protein release is the average particle
dimensions, which was 33 m in our previous work, and is 90 mhere (Pastor et al., 2011).
Particle dimension will influence the diVusion length within the carrier for the protein.
Recently, a new production method yielding planar mesoporous silicon microparticles
with a controlled thicknesses, porosity and pore sizes has been reported (Makushok,
Matveyeva & Pastor, 2012). These new kind of materials might be interesting for release
mechanism studies, since their lateral dimensions, perpendicular to the pore axis, will play
no important role in the release process.
MS-MPs can achieve a 2-week sustained release of antigenically
active BMP7
Based on promising data obtained with aCT protein, we tested MS-MP prototype C for
the controlled release of a therapeutic protein: BMP7. This protein is approved by FDA
and other regulatory agencies for orthopedic applications (OP-1 Putty and OP-1 Implant;
Stryker, Kalamazoo, Michigan, US), and it is delivered through a collagen sponge with
limited controlled release properties. This limited controlled release has been linked to
most of the treatment undesirable eVects (Lane, 2001). MS-MPs were loaded with BMP7
as described in ‘Protein loading in MS-MPs’, and the release kinetics of the protein was
analyzed. Consistent with the data obtained with aCT, a 2-week sustained release was
achieved (Fig. 2B). Once again, the release kinetics was characterized by low burst (<10%),
and by a sustained release profile for at least 14 days. Maximum release observed over
the experiment (28 days) was 70%. Significantly, the quantification of BMP7 in the
supernatant was performed by ELISA, and thus it guarantees the presence of the protein
in its antigenically-active form upon release. While antigenic activity is not a final proof of
biological activity, previous studies from our group using the same ELISA kit have found a
relation between antigenic BMP7 and bioactive protein in a glioblastoma cancer stem cell
model (Reguera-Nun˜ez et al., 2014).
The release profile was fitted to zero-order, first-order, Higuchi and to the
Kosmeyer–Peppas models (Wizard—Statistics, Visualization, Data Analysis, Predictive
Modeling, version 1.4; Evan Miller, US). Fitting to the first-order and Higuchi models
was adequate (p < 0:008 and p < 0:002, respectively), but the best fit was achieved with
the Kosmeyer–Peppas model (BMP released% D 10:4  t .days/0:64, p < 0:001). The
Kosmeyer–Peppas model is eVective to describe release systems where release kinetics
might depend on several factors. The diVusional exponent (nD 0:64) indicates a process of
anomalous diVusion (Korsmeyer et al., 1983; Peppas, 1985).
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The similarities between aCT and BMP7 release kinetics reflect their similar physico-
chemical properties. Indeed, BMP7 has a radius of gyration 3.5 nm (by analogy with
other BMPs, (Berry et al., 2006)) just slightly larger than aCT. It has also a basic isoelectric
point (8.1) close to that of aCT (9.5). These similarities result in consistent profiles for both
proteins, and suggest the robustness of the delivery technology.
In summary, we have achieved sustained release of BMP7 for at least two weeks by
using electrochemically synthesized MS-MPs. A preparation technology for the whole
therapeutic system is convenient, since both components, protein solution and pre-formed
empty MS-MPs, can be integrated together in an extemporaneous process. Due to the
recently reported osteointegration properties of the MS-MP carrier itself (Sun et al.,
2007), one of the immediate promising applications of this system would be in the bone
regeneration area.
CONCLUSIONS
Mesoporous silicon microparticles with controlled inner structure (pore size) can be
prepared by an electrochemical method, and loaded with proteins by simple adsorption
and solvent evaporation. Under optimized electrochemical conditions, these micropar-
ticles present a nanostructure with pore sizes below 10 nm, and this small pore size is
critical to provide sustained protein release over several days. The medical potential of the
electrochemically synthesized mesoporous silicon microparticles is suggested by the two
weeks sustained release profile of the osteogenic factor BMP7.
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